Stock 300558 BETTA PHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Betta Pharmaceuticals Co., Ltd.

Equities

300558

CNE100002DD9

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
40.54 CNY +3.66% Intraday chart for Betta Pharmaceuticals Co., Ltd. +12.49% -21.36%
Apr. 19 Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Jan. 04 C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd. CI

Business Summary

Betta Pharmaceuticals Co Ltd is a company mainly engaged in research, development, production and sales of innovative drugs for the treatment of malignant tumors. The Company's primary product is its self-developed icotinib hydrochloride (Conmana), a small molecule targeted anticancer drug used for the treatment of lung cancer. The Company is also engaged in promotional services, real estate leasing and other businesses.

Number of employees: 1,961

Sales per Business

CNY in Million2022Weight2023Weight Delta
Drug
98.4 %
2,342 98.6 % 2,417 98.4 % +3.17%
Promotional Services
0.9 %
19 0.8 % 22 0.9 % +15.37%
Factory Rental
0.7 %
14 0.6 % 16 0.7 % +11.48%
Others
0.0 %
0 0.0 % 1 0.0 % +126.44%

Sales per region

CNY in Million2022Weight2023Weight Delta
China
100.0 %
2,376 100.0 % 2,455 100.0 % +3.32%
Abroad
0.0 %
0 0.0 % 1 0.0 % +126.04%

Managers

Managers TitleAgeSince
Jia Tong CEO
 Chief Executive Officer 46 02-12-31
Lie Ming Ding CEO
 Chief Executive Officer 60 03-01-06
Jian Xun Fan DFI
 Director of Finance/CFO 53 15-12-31
Jiang Wan COO
 Chief Operating Officer 56 11-03-31
Jia Bing Wang CTO
 Chief Tech/Sci/R&D Officer 60 16-02-27
Jian Hao Shen IRC
 Investor Relations Contact - -
Ling Xi Wu SEC
 Corporate Secretary 41 20-09-23

Members of the board

Members of the board TitleAgeSince
Lie Ming Ding CEO
 Chief Executive Officer 60 03-01-06
Jiang Nan Cai BRD
 Director/Board Member 67 19-11-21
Jia Bing Wang CTO
 Chief Tech/Sci/R&D Officer 60 16-02-27
Jia Tong CEO
 Chief Executive Officer 46 02-12-31
Jiang Wan COO
 Chief Operating Officer 56 11-03-31
Yang Nan Zhang CHM
 Chairman 52 18-11-21
Fei Wu BRD
 Director/Board Member 47 17-11-26
Tian Xu BRD
 Director/Board Member 62 22-10-16
Jia Jia Xiao BRD
 Director/Board Member 41 22-10-16
Rong Wang BRD
 Director/Board Member 61 22-12-26

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 418,485,885 215,716,338 ( 51.55 %) 0 51.55 %

Shareholders

NameEquities%Valuation
Ningbo Kaiming Investment Management LP
19.35 %
80,064,000 19.35 % 453 M ¥
Xue Chao Wang
13.13 %
54,324,000 13.13 % 308 M ¥
Wenzhou Terui Venture Management Partnership LP
6.961 %
28,797,061 6.961 % 163 M ¥
Yin Xin Wang
3.403 %
14,075,564 3.403 % 80 M ¥
Lie Ming Ding
2.399 %
9,924,563 2.399 % 56 M ¥
LAV Management Co., Ltd.
2.306 %
9,540,500 2.306 % 54 M ¥
Hongde Fund Management Co., Ltd.
2.060 %
8,520,913 2.060 % 48 M ¥
Han Cheng Zhang
1.101 %
4,554,007 1.101 % 26 M ¥
Golden Trust Sinopac Fund Management Co., Ltd.
0.9927 %
4,106,400 0.9927 % 23 M ¥
Bosera Asset Management Co., Ltd.
0.8593 %
3,554,696 0.8593 % 20 M ¥
NameEquities%Valuation
Lie Ming Ding
56.97 %
739,978 56.97 % 4 M ¥

Holdings

NameEquities%Valuation
C4 THERAPEUTICS, INC.
8.12%
 5,567,928 8.12% 45,489,972 $

Company contact information

Betta Pharmaceuticals Co., Ltd.

355 Xingzhong Road Yuhang Economic & Tech Dev Zone

311100, Hangzhou

+

http://www.bettapharma.com
address Betta Pharmaceuticals Co., Ltd.(300558)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Specialty & Advanced Pharmaceuticals

Sales per Business

Sales per region

Ratings for Betta Pharmaceuticals Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
40.54 CNY
Average target price
54.14 CNY
Spread / Average Target
+33.53%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-21.36% 2.34B
MERCK KGAA Stock Merck KGaA
+5.31% 70.44B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+10.97% 8.94B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-16.83% 4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+43.48% 4.5B
YUHAN CORPORATION Stock Yuhan Corporation
+3.20% 3.85B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-29.67% 2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+8.38% 1.96B
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
+3.90% 1.65B
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300558 Stock
  4. Company Betta Pharmaceuticals Co., Ltd.